The
isolation of nanobodies (Nbs) from phage display libraries
is an increasingly effective approach for the generation of new biorecognition
elements, which can be used to develop immunoassays. In this study,
highly specific Nbs against the Alternaria mycotoxin tenuazonic acid (TeA) were isolated from an immune nanobody
phage display library using a stringent biopanning strategy. The obtained
Nbs were characterized by classical enzyme-linked immunosorbent assay
(ELISA), and the best one Nb-3F9 was fused with nanoluciferase to
prepare an advanced bifunctional fusion named nanobody–nanoluciferase
(Nb–Nluc). In order to improve the sensitivity and reduce the
assay time, two different kinds of luminescent strategies including
chemiluminescent enzyme immunoassay (CLEIA) and bioluminescent enzyme
immunoassay (BLEIA) were established, respectively, on the basis of
the single Nb and the fusion protein Nb–Nluc for TeA detection.
The two-step CLEIA was developed on the basis of the same nanobody
as ELISA, only with simple substrate replacement from 3,3′,5,5′-tetramethylbenzidine
(TMB) to luminol. In contrast with CLEIA, the novel BLEIA was conducted
in one-step new strategy on the basis of Nb–Nluc and bioluminescent
substrate coelenterazine-h (CTZ-h). Their half maximal inhibitory
concentration (IC50) values were similar to 8.6 ng/mL for
CLEIA and 9.3 ng/mL for BLEIA, which was a 6-fold improvement in sensitivity
compared with that of ELISA (IC50 of 54.8 ng/mL). Both
of the two assays provided satisfactory recoveries ranging from 80.1%–113.5%
in real samples, which showed better selectivity for TeA analogues
and other common mycotoxins. These results suggested that Nbs and
Nb–Nluc could be used as useful reagents for immunodetection
and that the developed CLEIA/BLEIA have great potential for TeA analysis.